

EXHIBIT 45

From: Walker, Donald
Sent: Thursday, February 23, 2012 11:52 AM
To: barbara.i.boockholdt@usdoj.gov
Cc: Trugman, Ina; John A. Gilbert, Jr.
Subject: January 26 meeting Follow-up

Dear Ms. Boockholdt:

Thank you again for the opportunity to meet with us so that we could discuss our Controlled Substance Monitoring Program and other compliance actions we have taken to reduce potential for diversion. I wanted to provide you with some additional information on topics we discussed at our January 26th meeting.

Follow up items:

1. You indicated that DEA had received only two suspicious order reports from McKesson during the time since our May 2008 settlement agreement. I have attached a summary document that lists customers (registrants) that McKesson identified as suspicious and reported to DEA. I have also identified several potential customers that through our diligence we chose not to conduct business with due to regulatory concerns.
2. I did discover a breakdown in the electronic reporting process we mutually established as required under the Memorandum of Agreement. The error was caused by electronically omitted orders. In several cases there were no omitted orders to transmit to the DEA. We did notify the local office but did not send a transmission to DEA headquarters.

To remedy this McKesson will back-up the transmissions and provide written notifications to your office, the local DEA office and the area DPM. I have also asked my IT team to contact the DEA IT to validate the systemic notification process.

3. I have confirmed that McKesson transmits ARCOS reports monthly.
4. At the close of the meeting we reported to you the systems issue that resulted in archived CSOS C-II orders being released, filled and shipped. We have accounted for all product and either received a Form 222 from the customer or the product was returned to McKesson. We are in the process of conducting and compiling a detailed reconciliation, which when complete will be forwarded to Kyle Wright. We have verbally notified all field offices with responsibility for the impacted distribution centers, and in some instances have provided written notifications per their request.
5. As a result of our discussion, we initiated an updated review of all of chain drug pharmacies and worked with the appropriate representatives to reduce authorized purchase limits on Oxycodone similar to the actions we

took with independents. McKesson also significantly reduced our threshold limits on independent pharmacies in the Delaware, Maryland, New Jersey and New York areas aligning with what the Company had already done in Florida.

In the future, I plan to communicate with you as needed via email (per your suggestion) to update you on actions and activities associated with our controlled substance monitoring. These communications will supplement McKesson's suspicious order reporting.

On behalf of McKesson, I want to assure you that the Company is taking the concerns expressed by you and your colleagues at the meeting very seriously and have put numerous actions in place to address them.

Thank you for your time and please email or call me with any questions.

Don Walker

SVP Distribution Operations

McKesson Pharmaceutical

415-983-9060

Ceased Selling Controls - Reported as Suspicious				
Customer Name	DEA #	City	State	Date of Action (enter as mm/dd/yyyy)
D&S Pharmacy	FD0127995	Woodhaven	MI	04/14/2010
Gwins Phcy	AG6027913	Anderson	IN	8/28/11
Laabs Pharmacy	AL3934014	Milwaukee	WI	9/30/11
Mykals Discount Phcy	FM1772739	Detroit	MI	01/28/2011
Mykals Discount Phcy #2	FM2299887	Detroit	MI	01/27/2011
Sav Max Pharmacy	BS9578519	Detroit	MI	10/05/2010
Six Mile Pharmacy	FS2233447	Detroit	MI	Feb-'09
The Medicine Shoppe	BR7456040	Belton	MO	3/1/08
Rockville Pharmacy	FR1486340	Rockville	MD	
Advanced Doctors Prescription Pharmacy	FA0408167	San Antonio	TX	Aug-'08
Generic Rx	FG1524657	Ft. Lauderdale	FL	11/7/11
Live and Let Live	AL0210168	Miami	FL	11/7/11
McGee's Pharmacy	BM7522837	Baton Rouge	LA	Jul-'11
Medical Plaza Pharmacy	AJ2074615	North Charleston	SC	May-'10
Medical Plaza Pharmacy of F	FM1239183	Plantation	FL	11/7/11
Modern Drug of Bayou Le Batre	BM2472570	Bayou Le Batre	AL	Feb-'09
Rodgersville Discount Pharmacy	BR2913108	Rodgersville	AL	Jul-'11
Century Plaza	BC9434046	Honolulu	HI	3/27/09
Drug Depot	FD2356245	SoCal	CA	8/1/11
Estrella Pharmacy	BE9738026	Phoenix	AZ	9/30/11
Express Pharmacy *	FE1766609	Bakersfield	CA	12/2/11
NuCare	RN0272322	SoCal	CA	11/1/10
Wellcare II	FW1294898	Las Vegas	NV	10/1/11
Castle Hill Drugs, Inc	FC0861345	Bronx	NY	11/8/11
Herndon Pharmacy & Medic	FH2358275	Herndon	VA	11/9/11
Life Pharmacy	FL1001077	New York	NY	1/3/12
Accokeek Pharmacy	BA6800216	Accokeek	MD	1/12/12
Family Meds Pharmacy	FF1958719	Waldorf	MD	1/13/12
Renaissance Pharmacy	FR0704040	Claymont	DE	2/9/09
Northeast Pharmacy	FN0841418	Philadelphia	PA	1/8/00
ATA Pharmacy	FA0689541	Philadelphia	PA	
Just Here Pharmacy	FJ1209724	Philadelphia	PA	
Lansdowne Pharmacy	FL0306414	Lansdowne	VA	7/15/08
Rockville Pharmacy	FR1486340	Rockville	MD	3/10/10
Castle Hill Drugs, Inc	FC0861345	New York	NY	11/8/12

* Customer corrected processes and we resumed selling controlled substances at minimum levels. Local office notified of this action.

Confidential / Exempt from FOIA. Subject to FRE 408.

MCK_WVA_000232